Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$663.11

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $650.69 14
Education $12.42 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1699985002?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $663.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tactile Systems Technology Inc $15.9611/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1180545938 CMS
E.R. Squibb & Sons, L.L.C. $7.4711/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942269 CMS
E.R. Squibb & Sons, L.L.C. $15.6611/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942271 CMS
Gilead Sciences, Inc. $12.4211/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1234362249 CMS
Regeneron Healthcare Solutions, Inc. $124.2709/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212863716 CMS
Tactile Systems Technology Inc $17.3709/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1180545936 CMS
E.R. Squibb & Sons, L.L.C. $15.8508/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942231 CMS
E.R. Squibb & Sons, L.L.C. $17.3708/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942209 CMS
E.R. Squibb & Sons, L.L.C. $124.9907/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942221 CMS
Caris MPI, Inc. $137.4105/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234278022 CMS
ABBVIE INC. $110.3204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201425951 CMS
Gilead Sciences, Inc. $24.5503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234478948 CMS
E.R. Squibb & Sons, L.L.C. $20.5902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942139 CMS
E.R. Squibb & Sons, L.L.C. $17.2601/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942129 CMS
E.R. Squibb & Sons, L.L.C. $1.6201/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184942131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $536.00 12/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681168
Principal investigator 1 Genentech, Inc. $28.00 12/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681162
Principal investigator 1 Genentech, Inc. $173.00 12/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681184
Principal investigator 1 Genentech, Inc. $114.00 12/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681202
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 12/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185543847
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185543841
Principal investigator 1 PFIZER INC. $9,203.85 12/08/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK46 INHIBITORBASED THERAPY No dispute reported 06/30/2026 1228735793
Principal investigator 1 Genentech, Inc. $1,350.00 11/14/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681856
Principal investigator 1 Genentech, Inc. $536.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680897
Principal investigator 1 Genentech, Inc. $22,420.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680949
Principal investigator 1 Genentech, Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211681004
Principal investigator 1 PFIZER INC. $956.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228713340
Principal investigator 1 PFIZER INC. $347.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228750337
Principal investigator 1 Genentech, Inc. $114.00 09/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680515
Principal investigator 1 Genentech, Inc. $173.00 09/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680517
Principal investigator 1 Genentech, Inc. $239.00 09/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680757
Principal investigator 1 Eli Lilly and Company $0.01 09/02/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187891758
Principal investigator 1 PFIZER INC. $1,125.00 09/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228757742
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 08/31/2025 Non-covered Recipient Entity
Texas Oncology - San Antonio
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232923900
Principal investigator 1 Genentech, Inc. $536.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680333
Principal investigator 1 Genentech, Inc. $28.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680353
Principal investigator 1 Genentech, Inc. $28.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680375
Principal investigator 1 Genentech, Inc. $173.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680777
Principal investigator 1 Genentech, Inc. $114.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680787
Principal investigator 1 Genentech, Inc. $70.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680821
Principal investigator 1 PFIZER INC. $295.00 08/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746717
Principal investigator 1 Genentech, Inc. $1,350.00 08/07/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681762
Principal investigator 1 Genentech, Inc. $114.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680351
Principal investigator 1 Genentech, Inc. $1,500.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680393
Principal investigator 1 Genentech, Inc. $114.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680419
Principal investigator 1 Genentech, Inc. $114.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680473
Principal investigator 1 Genentech, Inc. $173.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680511
Principal investigator 1 Genentech, Inc. $2,700.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680593
Principal investigator 1 Genentech, Inc. $173.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680599
Principal investigator 1 Genentech, Inc. $70.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680643
Principal investigator 1 Genentech, Inc. $173.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680751
Principal investigator 1 Genentech, Inc. $114.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680839
Principal investigator 1 Genentech, Inc. $536.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680849
Principal investigator 1 Genentech, Inc. $31,093.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680841
Principal investigator 1 PFIZER INC. $956.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746265
Principal investigator 1 PFIZER INC. $1,125.00 06/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228774298
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,010.50 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185543865
Principal investigator 1 AstraZeneca Pharmaceuticals LP $205,419.89 05/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185543857
Principal investigator 1 Genentech, Inc. $1,350.00 05/19/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681546
Principal investigator 1 PFIZER INC. $295.00 05/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228743845
Principal investigator 1 PFIZER INC. $295.00 05/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746714
Principal investigator 1 Genentech, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680079
Principal investigator 1 Genentech, Inc. $290.00 05/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681588
Principal investigator 1 Genentech, Inc. $8,850.00 05/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680161
Principal investigator 1 AstraZeneca Pharmaceuticals LP $104,924.57 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185543843
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,286.08 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185543849
Principal investigator 1 Genentech, Inc. $114.00 04/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680041
Principal investigator 1 Genentech, Inc. $173.00 04/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680083
Principal investigator 1 PFIZER INC. $956.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228743795
Principal investigator 1 Genentech, Inc. $536.00 04/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680227
Principal investigator 1 Genentech, Inc. $3,910.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,594.64 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185543863
Principal investigator 1 Genentech, Inc. $1,350.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681424
Principal investigator 1 Genentech, Inc. $293.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681426
Principal investigator 1 Genentech, Inc. $106.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681458
Principal investigator 1 Genentech, Inc. $1,363.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681468
Principal investigator 1 Genentech, Inc. $28.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681474
Principal investigator 1 Genentech, Inc. $28.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681672
Principal investigator 1 Genentech, Inc. $1,363.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681688
Principal investigator 1 Genentech, Inc. $1,363.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681690
Principal investigator 1 Genentech, Inc. $293.00 03/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681696
Principal investigator 1 PFIZER INC. $1,125.00 03/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228781472
Principal investigator 1 Genentech, Inc. $28.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679815
Principal investigator 1 Genentech, Inc. $1,500.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679889
Principal investigator 1 Genentech, Inc. $1,078.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679897
Principal investigator 1 Genentech, Inc. $28.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679915
Principal investigator 1 Genentech, Inc. $10,083.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679939
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 02/26/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185543855
Principal investigator 1 Genentech, Inc. $9,522.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681582
Principal investigator 1 Genentech, Inc. $12,962.00 01/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679835
Principal investigator 1 Eli Lilly and Company $5,550.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187892836
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,409.92 01/15/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185543839
Principal investigator 1 AstraZeneca Pharmaceuticals LP $86,847.60 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185543851
Principal investigator 1 AstraZeneca Pharmaceuticals LP $680.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185543853
Principal investigator 1 AstraZeneca Pharmaceuticals LP $680.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185543859
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,404.40 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185543861
Principal investigator 1 Eli Lilly and Company $956.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187892116
Principal investigator 1 Eli Lilly and Company $6,857.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187893128
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228749607
Principal investigator 1 PFIZER INC. $1,041.00 01/06/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228799304
Principal investigator 1 AstraZeneca Pharmaceuticals LP $83,235.06 01/03/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185543845